ED files chargesheet in Rs 211 crore Insurance Medical Services fraud

HYDERABAD : The Enforcement Directorate (ED) has filed a prosecution complaint (chargesheet) in the Rs 211 crore Insurance Medical Services (IMS) fraud under the Prevention of Money Laundering Act (PMLA).
Charges have been filed against the then IMS director Dr Devika Rani and 15 other accused, including representatives of several drug firms and pharma company owners.
ED had already attached properties worth Rs 144 crore. The accused had allegedly resorted to financial irregularities in the supply of medicines and other surgical kits to dispensaries and Employee’s State Insurance (ESI) hospitals across Telangana.
ED’s PMLA case is based on eight FIRs registered by the Anti-Corruption Bureau (ACB) against the accused for violations in the tender process, misappropriation of public funds and causing loss to the state exchequer. Dr Devika Rani and others are alleged to have conspired with medicine and medical equipment suppliers and issued purchase orders in violation of norms.

The chargesheet alleges that Dr Rani, in collusion with other IMS staff, violated all norms with supplier K Srihari Babu and also benami firms set up by the IMS chief and P Rajeshwar Reddy.

The prices of medical items were inflated, and indents and stock registers were fabricated. Another key accused, Dr K Padma, who was joint director IMS, was found to be siphoning off medicines and supplies in the name of medical camps.

Dr Rani and pharmacist Nagalaxmi allegedly conspired with PMJ Jewellers and purchased jewellery worth around `6.3 crore without bills using the scam money. The accused also invested in real estate. The scam mostly took place between 2015-16 and 2018-19. Several shell firms were floated to layer the money. The ED had attached villas, open plots, commercial shops and agricultural land parcels in Hyderabad, Bengaluru, and Noida.

Related Posts

  • Pharma
  • July 26, 2024
  • 132 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 133 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD